Show simple item record

dc.contributor.authorRondy, M
dc.contributor.authorWiessing, L
dc.contributor.authorHutchinson, S J
dc.contributor.authorMatheï, C
dc.contributor.authorMathis, F
dc.contributor.authorMravcik, V
dc.contributor.authorNorden, L
dc.contributor.authorRosińska, M
dc.contributor.authorScutelniciuc, O
dc.contributor.authorSuligoi, B
dc.contributor.authorVallejo-Ruiz de Leon, Fernando 
dc.contributor.authorVan Veen, M
dc.contributor.authorKretzschmar, M
dc.identifier.citationEpidemiol Infect. 2013 Mar;141(3):563-72.es_ES
dc.description.abstractMonitoring injecting drug users' (IDUs) health is challenging because IDUs form a difficult to reach population. We examined the impact of recruitment setting on hepatitis C prevalence. Individual datasets from 12 studies were merged. Predictors of HCV positivity were sought through a multilevel analysis using a mixed-effects logistic model, with study identifier as random intercept. HCV prevalence ranged from 21% to 86% across the studies. Overall, HCV prevalence was higher in IDUs recruited in drug treatment centres compared to those recruited in low-threshold settings (74% and 42%, respectively, P < 0·001). Recruitment setting remained significantly associated with HCV prevalence after adjustment for duration of injecting and recent injection (adjusted odds ratio 0·7, 95% confidence interval 0·6-0·8, P = 0·05). Recruitment setting may have an impact on HCV prevalence estimates of IDUs in Europe. Assessing the impact of mixed recruitment strategies, including respondent-driven sampling, on HCV prevalence estimates, would be valuable.es_ES
dc.description.sponsorshipThis study contributes to the work of the ‘European Study Group for Mathematical Modelling and Epidemiological Analysis of Drug-Related Infectious Diseases, coordinated by EMCDDA and RIVM with funding from WHO/Europe and the government of The Netherlands.es_ES
dc.publisherCambridge University Press es_ES
dc.subject.meshNeedle-Exchange Programs es_ES
dc.subject.meshPatient Selection es_ES
dc.subject.meshSubstance Abuse Treatment Centers es_ES
dc.subject.meshAdult es_ES
dc.subject.meshEurope es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHepatitis C es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshPrevalence es_ES
dc.subject.meshResearch Design es_ES
dc.subject.meshSelection Bias es_ES
dc.subject.meshSeroepidemiologic Studies es_ES
dc.subject.meshSubstance Abuse, Intravenous es_ES
dc.titleHepatitis C prevalence in injecting drug users in Europe, 1990-2007: impact of study recruitment settinges_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.contributor.funderWorld Health Organization (WHO/OMS) es_ES
dc.contributor.funderGovernment of Netherlands 
dc.identifier.journalEpidemiology and infectiones_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional